Double blind comparative trial of Abana and methyldopa for monotherapy of hypertension in Indian patients.
Abana is a herbomineral medicinal preparation with a property of down-regulation of beta-adrenergic receptors. A double-blind, parallel group study was conducted in 43 Indian men and women suffering from hypertension to evaluate the antihypertensive effect of Abana and compare it with that of methyldopa (M-DOPA). Twenty-one patients received 800 mg tds of Abana and 22 patients received 250 mg tds of M-DOPA for 4 weeks. Blood pressure and pulse rate were recorded at weekly intervals. Relevant clinical and biochemical investigations were carried out before and after treatment. In patients treated with Abana, there was a significant fall both in systolic B.P. (from 167 +/- 3.73 to 145 +/- 6.11 mmHg) and in diastolic B.P. (from 110 +/- 1.86 to 91 +/- 3.04 mmHg) at the end of 4 weeks. Similarly in patients treated with M-DOPA, systolic blood pressure was significantly reduced from 165 +/- 4.92 to 146 +/- 4.9 mmHg and diastolic blood pressure was reduced from 106 +/- 2.74 to 96 +/- 2.67 mmHg after 4 weeks. The onset of antihypertensive effect was earlier and there was a higher percentage of responders (80%) in the Abana-treated group. None of the patients had clinically or biochemically significant side-effects. The results of this study suggest that therapy with Abana proved highly effective in hypertensive patients.
Dadkar
V N
VN
Department of Pharmacology, L.T.M. Medical College, Bombay, Maharashtra, India.
Tahiliani
R R
RR
Jaguste
V S
VS
Damle
V B
VB
Dhar
H L
HL
D000328:Adult; D000368:Aged; D001794:Blood Pressure / Q000187:drug effects; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D006973:Hypertension / Q000188:drug therapy* / Q000378:metabolism / Q000503:physiopathology; D008297:Male; D008750:Methyldopa / Q000009:adverse effects / Q000627:therapeutic use*; D008875:Middle Aged; D008903:Minerals / Q000009:adverse effects / Q000627:therapeutic use*; D010936:Plant Extracts / Q000009:adverse effects / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic
D008903:Minerals; D010936:Plant Extracts; C064613:abana; D008750:Methyldopa